BioLine RX Ltd (BLRX) — Cash Flow Reinvestment Rate

Latest as of December 2023: 4.09x

BioLine RX Ltd (BLRX) has a Cash Flow Reinvestment Rate of 4.09x as of December 2023, reinvesting ILA20.41 Million (capex ILA18.00K plus investments ILA-20.39 Million) from operating cash flow of ILA4.99 Million. Check BLRX cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

4.09x

(Capex + Investments) / Operating CF

Total Reinvested

ILA20.41 Million

Capex + Investments

Operating Cash Flow

ILA4.99 Million

ILA

Capital Expenditures

ILA18.00K

ILA

BioLine RX Ltd Cash Flow Reinvestment Rate (2010–2010)

Historical reinvestment intensity for BioLine RX Ltd across 1 annual periods. Explore BioLine RX Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for BioLine RX Ltd (2010–2010)

Year-by-year capital reinvestment analysis for BioLine RX Ltd. For live market cap and broader valuation context, see how much is BioLine RX Ltd worth.

Year	Reinvestment Rate	Total Reinvested (ILA)	Operating CF	Capex	YoY Change
2010	0.06x	ILA660.94K	ILA11.46 Million	ILA660.94K	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow